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The p53 gene is the most frequent target of structural and functional genetic mutations in human cancer. 
Thus, considerable effort has been devoted to mapping the functional domains of p53 with regard to their 
impact on tumorigenesis in vivo. Studies have shown that the carboxy-terminal domain of p53 is sufficient for 
transformation in vitro. To determine whether a transdominant-negative p53 protein could be used to elicit a 
tissue-specific p53-nuU effect in vivo, we tested whether a carboxy-terminal p53 fragment (amino acids 
302-390) could abolish p53-dependent apoptosis in an established tumor progression model. We showed 
previously that loss of p53-dependent apoptosis accelerates brain tumorigenesis in a transgenic mouse model. 
Here, we show that the same effect can be elicited by expressing a dominant-negative p53 protein tissue 
specifically in the presence of wild-type p53. Transgenic mice in which pRb function has been disrupted and 
that coexpress a p53 carboxy-terminal dominant-negative fragment (p53DD) develop aggressive brain tumors 
mimicking genetic loss of p53 in this model. Inactivation of endogenous p53, which we show to be complexed 
with p53DD, results in a reduction in apoptosis and acceleration of tumorigenesis. These studies establish a 
mechanism for tissue-specific knock out of p53 function in vivo. 
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Mutation of the p53 gene is the genetic marker most 
frequently detected in human cancer (Levine et al. 1991; 
Greenblatt et al. 1994; Hinds and Weinberg 1994}. The 
p53 tumor suppressor functions as a negative regulator of 
cell proliferation either by its ability to induce growth 
arrest, programmed cell death or both (Donehower and 
Bradley 1993; Levine 1993; Picksley and Lane 1994; 
Haffner and Oren 1995). Based on current evidence, at 
least two models for the contribution of p53 inactivation 
to tumorigenesis can be envisioned (Lane 1992; Symonds 
et al. 1994a; Kastan et al. 1995). In the checkpoint con- 
trol model, p53-dependent growth arrest or apoptosis in 
response to DNA damage is lost upon p53 inactivation. 
Cells that have suffered oncogenic mutations unrelated 
to p53 survive and divide in the absence of the p53 
checkpoint, thereby undergoing the first stage of tumor- 
igenesis. A distinct and more direct role for p53 inacti- 
vation in tumor progression is predicted where perturba- 
tion of normal cell growth control by oncogenic events 
precedes p53 mutation. In this case, functional p53 sup- 
presses the survival of emerging tumor cells through 
p53-dependent apoptosis. Hence, during tumor develop- 
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ment selective pressure exists for the loss of p53 func- 
tion and p53 inactivation contributes directly to tumor 
progression. The extent to which either or both of these 
mechanisms explain the high frequency of p53 inactiva- 
tion and its role in human tumors is not yet clear. The 
impact of p53 inactivation may ultimately depend on 
cell type, stage of cell differentiation, or stage of tumor- 
igenesis in which p53 loss occurs. 
Experiments in transgenic mice using the p53-null an- 
imals have begun to elucidate the importance of inacti- 
vation of p53-dependent apoptosis during tumorigenesis 
and lend support to this notion. For example, the thy- 
mocytes of p53-null mice are defective in DNA damage- 
induced apoptosis (Clarke et al. 1993; Lowe et al. 1993) 
and are predisposed to tumorigenesis (Donehower et al. 
1992). This result is consistent with loss of a p53-depen- 
dent checkpoint contributing to tumor initiation. We re- 
ported recently that loss of p53-dependent apoptosis in 
aberrantly dividing brain epithelial cells results in rapid 
tumor progression (Symonds et al. 1994b}, consistent 
with the second model described above. Transgenic mice 
expressing a truncated SV40 large T antigen that induces 
abnormal proliferation by interfering with pRb family 
functions, but does not inactivate p53, develop tumors 
slowly because of abundant p53-dependent apoptosis. 
However, in a p53-null background, apoptosis is reduced 
dramatically and the rate of tumorigenesis is accelerated 
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(Symonds et al. 1994b). Other laboratories have shown a 
similar induction of p53-dependent apoptosis in mouse 
lens (Morgenbesser et al. 1994; Pan and Griep 1994) and 
retina (Howes et al. 1994), either by using human papil- 
loma virus (HPV) E6 and E7 expression (Pan and Griep 
1994}, E6 expression in p53 - / -  mice (Howes et al. 
1994), or Rb - / -  p53 - / -  mice (Morgenbesser et al. 
1994). 
Further studies are clearly required to determine the 
cell and developmental-specific mechanisms that define 
the tumor suppressor functions of p53. However, thus far 
there is no controlled way to specifically induce p53 loss 
in somatic cells during specific cell stages in vivo. Al- 
though tumor virus proteins such as HPV E6 inactivate 
p53, these proteins may have other uncharacterized ac- 
tivities, thereby complicating interpretation with re- 
spect to loss of p53 function. For example, recent studies 
show that in the mouse lens E6 interferes with both 
p53-dependent and p53-independent apoptosis (Pan and 
Griep 1995). 
In vitro studies using dominant mutants of p53 sug- 
gest that many of these mutant proteins interfere with 
wild-type p53 function, inactivating sequence-specific 
DNA binding and/or transcriptional activation 
(Shaulian et al. 1992; Unger et al. 1993; Zambetti and 
Levine 1993). The p53 protein appears to function as a 
tetramer and can form heteromeric complexes with mu- 
tant forms of p53, providing a mechanism for such a 
dominant-negative action (Milner et al. 1991; Stenger et 
al. 1992). A region within the carboxy-terminal domain 
(amino acids 330--390) in murine p53 is responsible for 
oligomerization (Shaulian et al. 1992; Sturzbecher et al. 
1992; Wang et al. 1994). p53 mutant proteins harboring 
this carboxy-terminal region possess a dominant-nega- 
tive function and can transform cells in culture, presum- 
ably by inactivating endogenous p53 (Unger et al. 1992). 
Moreover, overexpression of a truncated carboxy-termi- 
nal p53 fragment, containing amino acids 302-390, in- 
terferes with p53-mediated apoptosis in response to cy- 
tokine withdrawal in hematopoietic cells (Gottlieb et al. 
1994). 
To determine whether tissue-specific expression of a 
dominant-negative p53 mutant protein could inactivate 
p53 in vivo, we used a transgenic mouse model of tum- 
origenesis in which the biological consequences of p53 
inactivation has been established. In the brain epithelial 
tumor model described above, p53 loss results in a mea- 
surable reduction of tumor cell apoptosis and accelera- 
tion of tumor progression (Symonds et al. 1994b). This 
model provides a valid test for controlled somatic inac- 
tivation of p53 tumor suppression using a dominant-neg- 
ative p53 mutant. Here, we have generated transgenic 
mice that tissue specifically express a p53 mutant har- 
boring only the carboxy-terminal domain p53DD, and 
we have examined its ability to dominantly inactivate 
wild-type p53 function in vivo. We report that regulated 
expression of p53DD elicits tissue-specific inactivation 
of wild-type p53 tumor suppression in vivo. 
R e s u l t s  
Tissue-specific expression of p53DD in transgenic mice 
To test whether the p53DD protein (Fig. 1) could elicit a 
p53-null effect in tumor progression, we first directed its 
expression to the choroid plexus epithelium (CPE) of 
transgenic mice. In this tissue the absence of p53 alone 
normally has no effect but contributes to rapid tumori- 
genesis in the abnormally proliferating CPE of TgT121 
transgenic mice (Symonds et al. 1994b; summarized in 
Fig. 2). To achieve CPE expression we used the transcrip- 
tional control region of the transthyretin (TTR) gene that 
is expressed highly in CPE as well as in liver hepato- 
cytes. The transcriptional control elements required for 
proper tissue-specific expression of TTR-derived con- 
structs have been characterized previously (Costa et al. 
1988; Yan et al. 1990; Costa and Grayson 1991). Using 
transgenic mice, we showed that the TTR promoter tar- 
gets high-level expression to CPE in a copy number-de- 
pendent fashion (Yan et al. 1990). The level of expression 
in CPE ranges from undetectable with a single copy to 
5% of the total mRNA with 6-10 copies (Yan et al. 
1990). Consistently high liver hepatocyte expression is 
also achieved from the same vector. In this study liver 
expression provides a control tissue for p53DD effects 
because liver malignancies in p53-null mice are infre- 
quent (Donehower et al. 1992; Jacks et al. 1994). More- 
over, liver expression of p53DD provides an abundant 
resource for biochemical analyses. 
Figure 1. Functional domains of wild-type 
p53 and p53DD. Functional domains and 
regions of protein interaction of are desig- 
nated by shaded areas. The p53DD cDNA 
contains the first 13 codons followed by 
codons 302-390. 
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Figure 2. Summary of p53-dependent apoptosis and tumorigenesis. (A) Schematic diagram of wild-type SV40 T antigen (i) and T12 ~ 
proteins (ii-iv) with respect to tumorigenic functions. Status of tumor suppressor proteins, type of tumor, rate of tumorigenesis, and 
average percent apoptotic CPE cells are presented. Average percent apoptosis was quantitated from 10 random fields of vision. 
T~2~dnduced apoptosis on p53 + / + and p53 - / - backgrounds were determined in a previous study (Symonds et al. 1994b). {B) Schematic 
diagram of p53DD (/)and p53DD and T12 ~ proteins (ii) expressed tissue specifically in CPE and liver. Status of tumor suppressor 
proteins, tumor kinetics, average percent of total CPE cells expressing the p53DD protein, and average percent apoptosis were 
determined as indicated in Materials and methods. Two stages of tumor development were analyzed for mice coexpressing p53DD and 
Tl21. (a) 22-day-old mouse; (b) 85-day-old mouse. 
Analysis of p53DD expression in tissues 
of transgenic and nontransgenic littermates 
We generated five distinct founder mice harboring 
the TTRp53DD transgene {TgTTRp53DD-1 through 
TgTTRp53DD-5), four of which gave rise to F 1 offspring. 
These offspring were analyzed for p53DD expression in 
liver and brain by immunoprecip i ta t ion  analysis using 
the antibody PAb421, which  interacts wi th  the p53 car- 
boxyl te rminus  (Fig. 3A). Detection of p53DD was then 
performed by gel electrophoresis and Western blotting. 
As expected, p53DD was expressed specifically in liver" 
and brain (Fig. 3B), wi th  the level of brain expres- 
sion varying from line to l ine (data not shown). All 
four lines of mice showed abundant  p53DD expres- 
sion in liver. In brain, p53DD was detectable in two 
lines, TgTTRp53DD-2 and TgTTRp53DD-4. The 
TgTTRp53DD-2 mice, which  expressed the highest  level 
of p53DD protein in brain (data not shown), were used in 
all subsequent analyses. In. some cases (see below), 
TgTTRp53DD-4 mice  were examined as well. 
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Figure 3. Tissue-specifc expression of p53DD 
and complex formation with endogenous p53. (A) 
Schematic diagram of epitope map of wild-type 
p53 and p53DD indicating regions of recogni- 
tion for monoclonal antibodies used in B and C. 
(B) Immunoprecipitation-Western analysis for 
p53DD protein expression in liver, brain, and 
spleen tissues from a TgTTRp53DD transgenic 
mouse (DD) and nontransgenic littermate (N). 
Tumor tissue (control p53) from a transgenic 
mouse expressing a mutant T antigen (d11135) 
that stabilizes p53 was used to detect wild-type 
p53 (Symonds et al. 1993). Both wild-type and 
p53DD were immunoprecipitated with mouse 
monoclonal antibody PAb421, which recognizes 
an epitope in the carboxyl terminus (see A), fol- 
lowed by Western blot analysis using PAb421 as 
the primary antibody. Proteins were detected us- 
ing 12SI-labeled protein A. Autoradiographic film 
was exposed 24 hr with intensifying screens. To 
achieve antibody excess conditions for liver anal- 
ysis, 0.1 mg of total protein was used in the im- 
munoprecipitation compared with 2 mg for brain 
and 5 mg for spleen. For comparison of p53DD 
levels relative to brain, this represents -10-fold 
more specific cell protein in that hepatocytes ac- 
count for the majority of liver mass while chor- 
oid plexus comprises only 0.5% of brain mass. 
(C) Immunoprecipitation-Western analysis for 
detection of wild-type p53 complexed with 
p53DD using a battery of mouse monoclonal an- 
tibodies specific for epitopes present in wild-type 
p53 but not p53DD (see A). Control tumor tissue 
{as in B) served as a source of wild-type p53 that 
was immunoprecipitated with each of the indi- 
cated mouse monoclonal antibodies (lanes 1-4). 
Liver extracts from two TgTTRp53DD mice 
were analyzed for complex formation between 
wild-type p53 and p53DD (lanes 5-12). Immunoprecipitation of TgTTRp53DD liver extract with a nonspecific monoclonal antibody 
showed no bands comigrating with either p53 or p53DD (data not shown). Liver extract from a nontransgenic littermate served as a 
negative control (lanes 13-16). Autoradiographic film was exposed for 1 week with intensifying screens. The positions of wild-type 
p53, p53DD, and molecular mass markers (kD) are indicated. 
A representative immunoprec ip i ta t ion-Western  anal- 
ysis showing p53DD expression in brain and liver is 
shown in Figure 3B. As expected, no p53DD was de- 
tected in transgenic spleen (lane 5) or in any tissue of a 
nontransgenic l i t termate (lanes 2,4,6). Tumor  tissue 
from a transgenic mouse expressing SV40 T antigen, and 
thus high levels of wild-type p53, served as a control for 
p53 detection (Fig. 3B, lane 7). Although the endogenous 
level of p53 in TgTTRp53DD transgenic and nontrans- 
genic tissues was too low to observe in the exposure 
shown in Figure 3B, longer exposures of the immunoblo t  
showed a weak signal at the position of full-length p53 
present to similar levels in all transgenic and nontrans- 
genic tissues (data not  shown). 
Immunohis tochemica l  analysis of p53 expression was 
used to confirm the cell-type specificity of p53DD ex- 
pression. Endogenous p53 was not detectable under the 
conditions used (Fig. 4, insets), whereas a strong signal 
representative of p53DD was observed consistently in 
transgenic liver hepatocytes and brain CPE using the car- 
boxy-terminal-specific antibody PAb421 (Fig. 4A, B)bu t  
not with RA32C2, a monoclonal  antibody that  recog- 
nizes an epitope in wild-type p53 not present in p53DD 
(see Fig. 3A; data not shown). Expression of p53DD was 
distributed uniformly in both liver and choroid plexus, 
wi th  - 4 6 %  of hepatocytes and 32% of the brain epithe- 
lial cells staining positive (Figs. 4, A and B, respectively). 
p53DD forms a complex with endogenous wild-type 
p53 in vivo 
To determine whether  the p53DD expressed in vivo 
formed a complex with  wild-type p53 (as may  be pre- 
dicted for a dominant-negative function), coimmunopre-  
cipi tat ion-Western analysis was performed using a bat- 
tery of monoclonal  antibodies specific for p53 epitopes 
not present in p53DD (Fig. 3C). Coimmunoprecipi ta t ion 
of p53DD under these conditions indicates a complex 
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13-16}. These studies show that p53DD forms a complex 
with wild-type p53 in the tissues of transgenic mice and 
thus could serve to inactivate wild-type p53 by a domi- 
nant-negative mechanism involving complex formation. 
Figure 4. Immunohistochemical staining for p53DD protein in 
liver (A) and brain (B) using mouse monoclonal antibody 
PAb421. (Insets) In situ staining with the same antibody of tis- 
sues from nontransgenic littermates. Expression in liver is lim- 
ited to hepatocytes and in brain to CPE cells. Magnification, 
64x. 
between p53DD and the endogenous wild-type p53 pro- 
tein. Lysates from control tumor tissue that abundantly 
expressed wild-type p53 (lanes 1--4) and transgenic liver 
tissue from two separate TgTTRp53DD mice (lanes 
5-12) were incubated with monoclonal antibodies 
PAb246, PAb248, or RA32C2, which do not recognize 
p53DD, or PAb421, which recognizes both wild-type p53 
and p53DD (Fig. 3A). Wild-type p53 was readily immu- 
noprecipitated from the control tumor tissue (lanes 1- 
4) by all four antibodies. As expected, a much lower lev- 
el of wild-type p53 was detectable in livers from 
TgTTRp53DD transgenic (lanes 5-12)and nontransgenic 
littermates (lanes 13-16). Coimmunoprecipitation of 
p53DD with antibodies PAb246, PAb248, and RA32C2 
(lanes 5-7 and 10-12) indicates the presence of a com- 
plex between wild-type and mutant  p53 in each p53DD- 
expressing tissue. Neither p53 nor p53DD were detected 
using a nonspecific monoclonal antibody for immuno- 
precipitation (data not shown). The p53DD protein was 
clearly in excess of wild-type p53, as indicated by total 
amount of p53DD immunoprecipitated with PAb421 
(lanes 8,9). As expected, p53DD was not detectable in 
livers of nontransgenic mice with any antibody (lanes 
Inactivation of p53 by p53DD promotes rapid brain 
tumor progression 
We showed previously that the T121 mutant  SV40 T an-  
t i g e n  induces abnormal proliferation when expressed in 
the brain CPE of transgenic mice (Saenz-Robles et al. 
1994). This mutant  T antigen fragment consists of the 
amino-terminal 121 amino acid residues of T antigen 
(Pipas et al. 1983) and interacts with the pRb family pro- 
teins but lacks the p53-binding domain (Fig. 2A, ii-iv). 
Transgenic mice expressing T121 in CPE develop slow- 
growing brain tumors, with a tso = 26 weeks (Figs. 2A, ii, 
and Fig. 5; Saenz-Robles et al. 1994). The tumors develop 
slowly because of a high apoptotic index. However, ge- 
netic loss of p53 causes rapid tumor progression (tso = 3.5 
weeks) concomitant with a reduction in the apoptotic 
index (Symonds et al. 1994b; cf. Fig. 2, i, with Fig. 2, iv, 
and Fig. 5). Thus, assessment of tumor growth rate and 
CPE apoptosis in the TgT121 p53 + / + background pro- 
vides a biological assay for p53 inactivation. 
To test the hypothesis that expression of p53DD may 
elicit a tissue-specific p53-null phenotype, mice of 
l o o  : 
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Figure 5. Survival of transgenic mice in relation, to p53 func- 
tion. The percentage of mice of indicated genotypes surviving 
with time is shown. Survival times reflect the time of sacrifice 
dictated by the presence of bulged crania that signified the ter- 
minal phase of tumorigenesis. Each point on the graph desig- 
nates an individual mouse. Mouse genotypes are represented by 
the following symbols: (9 TgT121p53+/+; (A) TgT121p53-/-; 
(A) TgT,2~p53+/-; (E3) TgT; (I) TgTTRp53DD p53+/+; (O) 
TgT121 x TgTTRp53DD p53 + / + 
830 GENES & DEVELOPMENT 
 Cold Spring Harbor Laboratory Press on February 2, 2021 - Published by genesdev.cshlp.orgDownloaded from 
Tissue-specific inactivation of p53 
the TgT~2 ~ lineage were crossed wi th  mice of the 
TgTTRp53DD-2 or TgTTRp53DD-4 lineage such that 
T~2~ and p53DD would be coexpressed in the CPE. The 
wild-type p53 locus is fully intact in these doubly trans- 
genic mice. Expression of p53DD alone had no adverse 
effect either in liver or in CPE (as is the case for p53-nul l  
mice; Donehower et al. 1992; Jacks et al. 1994), and the 
TgTTRp53DD mice lived a normal life span (Fig. 5). 
However, coexpression of T121 and p53DD in the CPE 
facilitated rapid tumorigenesis  characteristic of TgT~21 
mice lacking a functional  p53 allele (Fig. 2, cf. A and B, 
and Fig. 5). Mice doubly transgenic for T~2 ~ and p53DD 
developed CPE tumors wi th  an accelerated rate (tso = 7 
weeks) compared wi th  mice expressing T121 alone 
(tso = 26 weeks)(Fig. 5). The slightly slower rate of tumor 
growth in TgT121 p53DD-expressing mice compared 
with p53-null mice (tso = 3.5 weeks) can be explained by 
the fact that p53DD was expressed in only - 3 2 %  of the 
CPE cells (Fig. 4B). In support of this explanation, tumor 
growth rate in TgT]2~/TgTTRp53DD mice was similar  
to that of transgenic mice  expressing wild-type T antigen 
in a s imilar  fraction of CPE cells {tso--6 weeks; Fig. 5; 
Chen and Van Dyke 1991). These results indicate that 
tissue-specific expression of p53DD can functionally in- 
activate wild-type p53 leading to rapid brain tumor pro- 
gression. 
Expression of p53DD in proliferating CPE 
correlates with reduced apoptosis 
To determine whether  p53DD expression was effective 
in reducing the p53-dependent apoptosis associated wi th  
rapid tumor progression, we analyzed apoptotic indices 
in CPE cells coexpressing p53DD and T121 or T12~ alone. 
We showed previously that T121 is expressed in a high 
fraction (>90%) of the CPE cells in TgT]2~ transgenic 
mice (Saenz-Robles et al. 1994). Figure 6 shows immu-  
nohis tochemical  staining for apoptotic cell nuclei  and 
p53DD protein in brain sections of T12 ~ p53DD doubly 
transgenic mice at two ages. Apoptotic indices relative 
to that of T121 p53 +/+ mice and the percentage of 
p53DD-expressing cells are presented in the histogram of 
Figure 6E. Because only a fraction of the CPE cells ex- 
press p53DD in young mice, we correlated apoptosis 
with p53DD expression by detecting both events in the 
same section. Although the apoptotic index was reduced 
only slightly in young T121 p53DD doubly transgenic 
mice (85% that of T121 mice; Fig. 6A, B,E), most apop- 
totic cells did not express p53DD (Fig. 6B). The apoptotic 
index was reduced dramatical ly when, at later times, 
p53DD-expressing cells became much  more abundant  
(presumably because of their selective advantage} (Fig. 
6C-E). The CPE apoptotic indices in four independent 
T12~/p53DD mice wi th  a high fraction of p53DD-posi- 
tive CPE cells were comparable wi th  that of mice ex- 
pressing T121 on a genetically p53-null background (17%, 
25%, 11%, and 6.5% compared wi th  15% of the T~2~ 
control, respectively; Fig. 6E}. These results indicate that 
p53DD expression in the presence of wild-type p53 leads 
Figure 6. Expression of p53 decreases apoptosis. The CPE of 
TgT~2~/TTRp53DD mice at two different ages was analyzed for 
cells expressing p53DD protein (using PAb421} and for apop- 
totic nuclei (using TUNEL) in thin brain tissue sections. {A} 
Immunohistochemical staining for apoptotic nuclei; (B)p53DD 
protein simultaneous with apoptotic nuclei in a 22-day-old 
mouse. Arrows in B point to regions of CPE ceils expressing 
p53DD protein. (C) In situ detection of p53DD-expressing cells; 
(D) apoptotic nuclei (as described above) in an 85-day-old Tlal 
TTRp53DD mouse. The arrow in D points to apoptotic nucleus. 
Magnification in A-D, 128x. (E) Apoptotic index relative to 
p53DD expression. Level of apoptosis and number of p53DD- 
expressing CPE cells were quantified (see Materials and 
methods) for TgT121p53 +/+, TgT121 p53 / and five 
TgT121xTgTTRp53DD mice. Relative percent apoptosis com- 
pared with the TgT12 ~ p53 + / * control value is represented on 
the left y-axis corresponding to the stippled bars and the per- 
centage of total CPE cells expressing p53DD is represented on 
the right y-axis corresponding to the solid bars. Data for 
TgT121P53 +/+ and TgT121p53 / mice shown for comparison 
were obtained in a previous study (Symonds et al. 1994b}. 
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to a reduction in apoptosis consistent with the inactiva- 
tion of p53 function by a dominant-negative mechanism. 
Discussion 
We have demonstrated here that tissue-specific expres- 
sion of the p53 carboxy-terminal fragment p53DD, in the 
presence of wild-type p53, elicits a p53-null phenotype 
in transgenic mice. The TgT12~ tumor model served here 
as a biological test for p53 inactivation during tumori- 
genesis in an intact animal model system. These ani- 
mals, which express the T121 truncated SV40 T antigen 
specifically in brain epithelium, develop slow growing 
tumors. The tumor cells proliferate abnormally, a re- 
sponse dependent on the ability of T~2~ to interfere with 
the function of one or more pRb family members. In the 
presence of functional p53, however, these cells undergo 
p53-dependent apoptosis resulting overall in slow tumor 
growth. Genetic inactivation of p53 results in a reduc- 
tion of apoptosis and significant acceleration of tumor 
growth (Symonds et al. 1994b). This phenotype was re- 
produced here by expression of p53DD in T~2~-express- 
ing brain epithelium in the presence of wild-type p53. 
Thus, p53DD acts as a dominant-negative inhibitor of 
p53 function in vivo. 
The p53DD transgene was shown to be expressed spe- 
cifically in brain CPE and in liver hepatocytes by in situ 
immunohistochemical and immunoprecipitation-West- 
ern blot analyses (Figs. 3 and 4, respectively). Overex- 
pression of p53DD in these cells of otherwise normal 
mice did not result in abnormalities, and thus the 
TgTTRp53DD mice have normal life spans. Hence, over- 
expression of a protein that interferes with p53 function 
is not toxic under normal circumstances, and p53DD 
does not appear to possess dominant oncogenic activity 
distinct from wild-type p53 inactivation. The fact that 
abnormalities are not induced in hepatocytes and brain 
epithelium upon inactivation of p53 by p53DD is con- 
sistent with observed abnormalities in p53-null and 
p53-heterozygous mice. p53-null mice do not develop 
abnormalities in either cell type but, rather, succumb 
predominantly to T-cell lymphomas at -4--5 months of 
age (Donehower et al. 1992; Jacks et al. 1994). The 
p53 + - mice develop a broader spectrum of tumors than 
do p53-null mice; however, liver and brain abnormali- 
ties have been reported only infrequently (Jacks et al. 
1994; Harvey et al. 1995). 
Although p53DD had no impact on normal nondivid- 
ing brain epithelial cells, its presence accelerated tumor 
development significantly when coexpressed with the 
T~2~ T antigen fragment. As with genetic inactivation of 
p53, the acceleration of tumor growth correlated with a 
reduction in apoptosis. Because only a fraction of CPE 
cells (-32%) expressed p53DD, tumors developed at a 
slower rate compared with that of T12~ p53 - / -  mice 
(tso --- 7 weeks vs. 3.5 weeks, respectively) but accelerated 
significantly compared with TgT121P53 + / + mice (tso = 26 
weeks). The fact that p53DD may not be expressed in all 
cells of a given tissue when introduced as a transgene 
provides an experimental advantage, as cells that are 
functionally p53 + and p53-  can be assessed in the same 
tissue. This situation reflects more accurately what oc- 
curs in a developing neoplasm upon somatic inactivation 
than does a genetic null in which the gene is never ex- 
pressed. In the case of the doubly transgenic T]21/ 
TTRp53DD mice, CPE cells that expressed p53DD had a 
clear growth advantage over those expressing T121 alone. 
This was apparent upon examining the CPE at different 
ages where multifocal tumor growths were consistently 
p53DD positive. Moreover, there was a correlation be- 
tween the fraction of cells expressing p53DD and a re- 
duction in apoptotic index, with predominantly nonex- 
pressing cells undergoing apoptosis before focal growth. 
This observation supports the previous indication that 
the selective growth advantage is a reduction in cell 
death. 
The mechanism of p53 inactivation by p53DD likely 
involves hetero-oligomerization with the endogenous 
p53. p53 binds specific DNA optimally as a tetramer 
(Shaulian et al. 1992; Unger et al. 1993; Wang et al. 
1994), and wild-type p53 is capable of oligomerization in 
normal tissues (Wang et al. 1994). Previous studies in 
tissue culture have shown that p53DD interacts with 
wild-type p53 and also interferes with p53 DNA-binding 
activity (Shaulian et al. 1992, 1995). In this study we 
showed that p53DD can dominantly inactivate the tu- 
mor suppression function of p53. Furthermore, we dem- 
onstrated that p53DD forms a complex with wild-type 
p53 in vivo (Fig. 3}. Using antibodies specific for the full- 
length protein but that did not interact with the mutant  
protein directly, p53DD was readily coimmunoprecipi- 
tated from tissue extracts with wild-type p53. Most if 
not all of the endogenous p53 in p53DD-expressing cells 
was likely in such complexes because p53DD was 
present in vast excess (Fig. 3C). 
Our studies show compellingly that tissue-specific ex- 
pression of p53DD can be used as a valuable tool to study 
a variety of tumors at various developmental stages in 
existing mouse models. Although p53 is the gene af- 
fected most frequently in human cancer, it is not clear 
whether a common mechanism associated with p53 loss 
contributes to the development of tumors of different 
cell origins. Mutations in p53 arise in most if not all 
histogenic classes of tumors (Hollstein et al. 1991). In 
some cases, p53 mutation can be detected early in the 
development of malignancy, whereas such mutations 
consistently appear in other cancer types later in progres- 
sion (for review, see Hollstein et al. 1991). The conse- 
quences of p53 loss may be different, depending on the 
stage of tumorigenesis at which p53 inactivation occurs. 
For example, p 5 3 - / -  and p53 + / - mice develop a differ- 
ent spectrum of tumors for currently unknown reasons 
(Harvey et al. 1993; Jacks et al. 1994) Although mouse 
models have contributed significantly to our understand- 
ing of p53 function, currently we are limited to studying 
the complete absence of p53 (as in a p53-null  genetic 
background) or stochastic loss of p53 (as in p53-hetero- 
zygous mice). The latter situation is most similar to 
what occurs in the development of human tumors but is 
not regulatable experimentally. Our studies on p53DD 
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offer a third, more  man ipu lab l e  sy s t em for s tudy ing  p53 
loss dur ing specific stages of tumor igenes i s  in mu l t ip l e  
cell types and provide an  a l te rna t ive  to the  use of viral  
proteins,  such as HPV E6. In this  s tudy  targeted inacti-  
va t ion  of p53 was  accompl i shed  us ing  a cell-specific pro- 
mote r  to drive p53DD expression.  Addi t iona l  versa t i l i ty  
could be accompl i shed  us ing  an inducib le  promoter  sys- 
t em or w i t h  somat ic  del ivery  of viral  vectors  expressing 
p53DD. Because we  have  shown  tha t  p53DD elici ts  a 
biological  effect ident ica l  to genet ic  loss of p53, these  
s tudies  should  provide a tool for probing cell- and stage- 
specific m e c h a n i s m s  of p53 loss in  the con t r ibu t ion  to 
tumor igenes is .  
Materia ls  and m e t h o d s  
Plasmids 
The construction of the expression vector containing the trun- 
cated T antigen gene pT121 (formerly pLST1137) was described 
previously (Chen and Van Dyke 1991; Chen et al. 1992). The 
vector used for expression of p53DD (TTR1ExV3) has been de- 
scribed (Wu et al. 1996). It contains transcriptional control se- 
quences from the mouse TTR gene required for efficient and 
tissue-specific expression in the brain CPE and liver. Site-di- 
rected point mutagenesis was used to eliminate the ATG 
codons in the first and second exons of TTR and to provide a 
StuI restriction site for cDNA insertion in the second exon. The 
TTRp53DD plasmid was constructed by digesting the expres- 
sion plasmid pTTRExV3 with StuI followed by the generation of 
blunt ends with Klenow. The pSPDD described previously 
(Shaulian et al. 1992) was digested with BamHI and XbaI and 
blunted with Klenow. The 650-bp coding fragment was isolated 
and then ligated into pTTRExV3. The construct pTTRp53DD 
was confirmed by sequence analysis. The resulting p53DD-cod- 
ing segment contains the murine p53 initiation codon and the 
amino-terminal 13 codons followed by carboxy-terminal codons 
302-390 (Fig. 1). 
Production and screening of transgenic mice 
The plasmid pTTR-p53DD was digested with HindIII, and the 
4.7-kb fragment containing the TTRp53DD gene was isolated 
and microinjected into fertilized mouse eggs (B6D2F 1 x B6D2F 1; 
Jackson Laboratories, Bar Harbor, ME) as described previously 
(Chen and Van Dyke 1991; Chen et al. 1992). Transgenic off- 
spring were identified by PCR analysis of genomic DNA iso- 
lated from tail samples using two sets of primers, one that hy- 
bridizes to sequences within the TTR gene promoter region and 
detects the endogenous TTR gene (internal control) as well as 
the transgene (5'-TCGCGAATTCGGAGCTTGTGGATCTGT- 
GTGACGGC-3' and 5'-CTCGAGATCTGGGATTGGGTGT- 
GTC-3') and a transgene-specific primer set that hybridizes to 
the TTR intron and to p53DD (5'-CTTTTTGCACCATG- 
CACCTTTC-3' and 5'-TTGGTCTTCAGGTAGCTGGAGTG- 
3', respectively). Generation, screening, and characterization of 
TgTI~ 1 mice were described previously (Saenz-Robles et al. 
1994). 
Immunoprecipitation and immunoblotting analysis 
Tissues were used fresh or stored frozen at -80~ before anal- 
ysis. Extracts were prepared as described previously (Symonds 
et al. 19931. The protein extract containing 5 mg of total protein 
from spleen, 2 mg from brain, 0.1 mg from liver, and 0.5 mg 
from thymus was precleared with Staphylococcus aureus-pro- 
tein A followed by incubation with the appropriate monoclonal 
antibody (300 ~1 of hybridoma supernatant) for 1 hr at 4~ The 
antibody-protein complexes were immunoprecipitated with S. 
aureus, the immunoprecipitates washed three times with 
SNNTE [5% sucrose, 0.5 mM NaC1, 0.1% NP-40, 50 mM Tris 
(pH 7.4), and 5 mM EDTA] followed by one wash with NTE [50 
mM NaC1, 10 mM Tris (pH 7.4), and 1 mM EDTA], resuspended 
in Laemmli protein loading buffer, and electrophoresed in 15% 
polyacrylamide-SDS gels. Proteins were transferred to nitrocel- 
lulose (BioBlot-NC, Costar), and immunoblotting was per- 
formed as described previously using L2SI-labeled protein A de- 
tection (Symonds et al. 1993). To detect p53/p53DD complexes, 
liver lysate containing 5 mg of total protein was used for each 
immunoprecipitation. The following antibodies were used for 
immunoprecipitation: PAb421 (Harlow et al. 1981), RA32C2 
(Coffmann and Weissman 1981), PAb246, and PAb248 (Wade 
Evans and Jenkins 1985). The approximate locations of epitopes 
are shown in Figure 3A. A monoclonal antibody specific for 
adeno-associated virus capsid proteins (provided by R. Samul- 
ski, University of North Carolina, Chapel Hill) was used as a 
nonspecific control for p53 immunoprecipitation. 
Histology and imrnunohistochemistry 
Brain tissues were fixed in 10% neutral-buffered formalin 
(Sigma) for 16--20 hr, washed in dH20 followed by 70% ethanol, 
and embedded in paraffin. Tissue sections (6 ~) were deparaf- 
finized by successive washes in Hemo-De (Fischer) followed by 
dehydration in graded ethanols. For immunostaining, deparaf- 
finized sections were incubated with trypsin (1 mg/ml) in phos- 
phate-buffered saline (PBS) for 30 min at room temperature. 
Sections were blocked with 5% normal goat serum (NGS) in 
PBS for 30 min at room temperature, by incubation with pri- 
mary antibody in 5% NGS in PBS for 1 hr at room temperature. 
A mouse monoclonal antibody to p53 that recognizes amino 
acids 370-378 in the carboxyl terminus (PAb421; Harlow et al. 
1981) was used to detect p53DD. The slides were washed in PBS 
and incubated with biotinylated anti-mouse IgG (diluted 1:300 
to 1:500 with NG8 in PBS) for 30 min at room temperature. 
Immunocomplexes were detected using the Vectastain ABC al- 
kaline phosphatase kit (Vector) according to the manufacturer's 
instructions. 
In situ detection of apoptosis was performed on tissue sec- 
tions alone or after immunohistochemical staining. Endoge- 
nous peroxidase activity was quenched with 0.1% H202 in PBS. 
Apoptotic cells were detected using the in situ Apoptag kit (On- 
cor) according to the manufacturer's protocol except that the 
slides were incubated with terminal deoxytransferase for 15 
min at room temperature as described previously (Symonds et 
al. 1994b). Quantification was performed by counting 10 ran- 
domly chosen fields of vision at a magnification of 400x per 
tissue section. The counts were averaged to obtain the average 
number of cells expressing p53DD or the average apoptotic in- 
dex. 
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